Iris Publishers - Current Trends in Clinical & Medical Sciences (CTCMS)
Atypical clinical presentation of COVID-19: a case of Guillain-Barrè Syndrome related to SARS-Cov-2 infection
Authored by Angelo Michele Carella
In these months the diffusion of a
novel beta coronavirus, known as Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2), is causing a worldwide public health emergency originated in
Wuhan, China. The novel coronavirus was reported to cause symptoms resembling
the severe acute respiratory syndrome (SARS-CoV) by previous coronavirus in the
years 2002 and 2003. Genetic sequencing of the virus suggests that it is
closely linked to the SARS coronavirus. Both share the same receptor,
angiotensinconverting enzyme 2 (ACE2) and therefore this virus was named
SARS-CoV-2 [1, 2].
SARS-CoV-2 is very contagious and
its rapid propagation has spread globally; there are three main transmission
routes of COVID-19 infection: droplets, contact and aerosol transmission [3].
The gold standard for diagnosis of SARS-CoV-2 infection is real-time polymerase
chain reaction fluorescence (RT-PCR) for detecting SARS-CoV-2 nucleic acid in
samples of sputum or throat swab and in secretions of upper respiratory tract.
Other potential diagnostic method might be the detection of specific IgM and
IgG antibodies against SARS-Cov-2 in blood samples, although this method seems
more appropriate for population screening [4].
The most prevailing onset symptoms
of this infection, after an approximate incubation period of five days on
average, are fever, cough, myalgia and fatigue, but also diarrhea, leg pain,
dysgeusia and hyposmia [5, 6]. Although most patients infected by SARSCoV- 2
are asymptomatic or develop mild to moderate symptoms, a subset of patients
develops serious interstitial pneumonia that may quickly progress to severe
acute respiratory distress syndrome (ARDS), septic shock and fatal multi organ
dysfunction that are the most severe clinical manifestations of SARS-Cov-2
infection [7].
High serum levels of Interleukin-6
(IL-6) and D-Dimer seem closely related to the occurrence of severe COVID-19
and their combined detection may be very useful for early prediction of severe
COVID-19 patients; moreover, the patients present frequently lymphopenia and
neutrophilia, hypoalbuminemia, high serum levels of alanine aminotransferase,
lactate dehydrogenase, C-reactive protein, and sudden oxygenation deterioration
[8].
Given that acute respiratory
syndrome is the hallmark feature of severe COVID-19, most initial studies have
focused on its impact on the respiratory system. However, accumulating evidence
suggests that SARS-CoV-2 also infects other organs and can affect various body
systems [9]. The expression and distribution of ACE2 in multiple human organs,
including nervous system and skeletal muscles, suggests that SARS-CoV-2 might
have a neuroinvasive potential and its impact on the nervous system might occur
through direct infection or via secondary effects relating to intense systemic
inflammatory response linked to viral infection [10-12]. Indeed, in severe
cases of COVID-19 it has been shown a massive release of proinflammatory
mediators and cytokines, in particular Interleukin-6 (IL-6) and Interleukin-1
(IL-1), linked to viral replication and leading to cytokine release
syndrome-like [13].
Recent retrospective data from
China showed that 36% of 214 SARS-CoV-2 infected patients had neurological
manifestations, including acute cerebrovascular disease and impaired
consciousness [14]; in addition, a first case of encephalitis with SARS-CoV-2
RNA detection in cerebrospinal fluid (CSF) was reported [15].
In this case report we describe an
atypical clinical presentation of COVID-19, started as Guillain-Barré Syndrome
(GBS) and without typical respiratory symptoms of SARS-Cov-2 disease.
Case Report
A 62-years- old male patient was
admitted in our Internal Medicine Unit, complaining for some days of acute
progressive symmetric weakness started in distal lower extremities and
progressed to proximal limbs. Neurological manifestations were associated with
pain, paraesthesias, peripheral oedema, severe fatigue and serious functional
limitation in the movements. The patient denied fever, cough, respiratory
symptoms or diarrhea and his past medical history was unremarkable. Previous
corticosteroid treatment was already started few days before.
At admission, the patient had not
fever nor dyspnea and was conscious; blood pressure was 120/75 mmHg, heart rate
110 beats/ minute and oxygen saturation 98% on air; clinical examination was
normal except for asymmetric weakness in all limbs, presenting 1/5 value of
Medical Research Council scale at lower extremities and 2/5 value at upper
extremities, without cranial nerves involvement.
No abnormalities were found in
chest-X-ray, transthoracic echocardiogram and abdominal ultrasonography;
electrocardiogram showed sinus tachycardia (105 beats/minute). The patient
underwent cervical and brain magnetic resonance imaging that revealed normal
finding except for enhancement of the nerve roots.
Abnormal laboratory tests were
found as following: high serum levels of C-reactive protein (447 mg/l),
erythrocyte sedimentation rate (92 mm/hour), ferritin (1857 ng/ml),
procalcitonin (8,7 ng/ ml), lactate dehydrogenase (574 IU/l), D-dimer (935
ng/ml), glucose (211 mg/dl), fibrinogen (1013 mg/dl), myoglobin (702 ng/ ml)
and Troponin I-hs (72 ng/l); severe hypoalbuminemia (1.57 g/dl), mild
normocytic nomochromic anemia, thrombocytopenia (69000/μl) and marked
lymphocytopenia (260/ μl) with normal white cells count (9200/μl) were also
observed. No abnormalities were found in peripheral smear except poor
platelets, aPTT and PT/ INR values were in normal range and blood gas analysis
revealed respiratory alkalosis with high lactates (3.3 mmol/l) and normal
oxygen saturation.
Non-organ specific auto-antibodies
(ANA, AMA, ENA, ds- DNA, ANCA) resulted negative as well as anti-HIV test and
antiviral antibodies against Epstein-Barr virus, Cytomegalovirus, Herpesvirus,
Togavirus, and hepatitis C and B markers; both urine and blood cultures were
negative. CFS analysis by lumbar puncture revealed normal cells count and lack
of albumin-cytological dissociation.
Given that GBS was suspected, the
patient started therapy based on intravenous immunoglobulin (IGIV 0.4 g/kg for
a planned 5-day course), steroid therapy (Methylpredisolone 1mg/kg) and
subcutaneous Enoxaparin (6000 IU daily).
Considering the laboratory
abnormalities and the COVID-19 outbreak we decided to search SARS-Cov-2 by
subjecting the patient to nasopharyngeal swab which resulted positive on RT-PCR
assay. The patient was transferred to Infectious Deseases Unit where he
continued IGIV therapy and began treatment with tocilizumab, hydroxychloroquine
and plasmapheresis. The patient currently continues hospitalization in this
clinical setting.
Discussion
In this study, we report a case of
atypical infection of SARSCoV- 2 initially occurred as acute GBS. GBS is
immune-mediated demyelinating disease of the peripheral nerves and nerve roots
(polyradiculoneuropathy) that is usually triggered by various infections. At
the moment six pathogens have been associated with GBS in case-control studies:
Campylobacter Jejuni, Cytomegalovirus, Hepatitis E virus, Mycoplasma
Pneumoniae, Epstein-Barr virus and Zika virus. Although the clinical
presentation of the disease is heterogeneous, the classic manifestations of GBS
are progressive, ascending and symmetrical flaccid paralysis of limbs, along
with areflexia or hyporeflexia and with or without cranial nerve involvement.
Pain is frequently reported and can be muscular, radicular or neuropathic [16].
Disease onset is acute or subacute
and can progress over days to a few weeks. Diagnosis of GBS is based on the
patient history and neurological, electrophysiological and CSF examinations.
The classic finding in GBS is the combination in the CSF of elevated protein
levels and normal cell count, known as albumin-cytological dissociation.
However, protein levels are normal in 30-50% of patients in the first week
after disease onset and normal CSF protein levels do not rule out a diagnosis
of GBS [16, 17].
Emerging evidence indicates that
SARS-CoV-2 infection may cause neurological complications and some cases of GBS
associated with SARS-CoV-2 infection have been recently observed in Italy,
China and in other countries; in these cases the interval of 5 to 10 days
observed between the onset of viral illness and the first symptoms of GBS
resulted similar to the interval observed in GBS cases that occur during or
after other infections. In one case, fever and respiratory symptoms developed 7
days after the onset of GBS symptoms so that parainfectious profile pattern of
GBS, instead of classic post-infectious profile, was suggested [18-21]. In our
case the patient never showed respiratory symptoms nor fever; laboratory
abnormalities, in particular high inflammatory parameters, lymphocytopenia and
thrombocytopenia, suggested an infectious disease such as SARS-CoV-2.
The link between viral infection
and neurological manifestations is not yet clear; neurotropic and neuroinvasive
capabilities of other coronaviruses such as SARS-CoV and MERS-CoV were
described in humans and the neurological manifestations included encephalitis,
polyneuropathy and GBS [22, 23]. The SARS-Cov-2 impact on the nervous system
could be through direct infection or via secondary effects relating to intense
systemic inflammatory response linked to viral infection [2, 11]. Recent report
of GBS associated with SARSCoV- 2 raises concern for this virus to be a
possible trigger [19]. It may be hypothesized that an aberrant immune response
to the infection determines a serious inflammatory damage to peripheral nerves
with molecular mimicry reaction, although the pathogenesis in not fully
understood [16, 24].
We speculate that SARS-CoV-2
infection may be responsible for GBS development in this patient; we think
SARS-Cov-2 may stimulate inflammatory cells causing massive release of
pro-inflammatory mediators and cytokines, triggering immune-mediated
neuropathy. Among various hypotheses it cannot be excluded that SARS-CoV-2 may generate
auto-antibodies against specific gangliosides.
Conclusion
Apart asymptomatic patients,
awareness of atypical clinical presentation of SARS-Cov-2 infection is
remarkable and essential to avoid its contagious spread, particularly on
hospital admission. This clinical case suggests the need to also consider
potential neurological manifestations of COVID-19 and physicians should
consider the potential link between GBS and SARS-CoV-2 infection. Therefore,
during this epidemic era of COVID-19, to ensure SARSCoV- 2 infection is never
overlooked, clinical symptoms of GBS should be considered in COVID-19
differential diagnosis to avoid delayed diagnosis or misdiagnosis
To read more about this article: https://irispublishers.com/ctcms/fulltext/atypical-clinical-presentation-of-covid-19.ID.000526.php
Indexing List of Iris Publishers: https://medium.com/@irispublishers/what-is-the-indexing-list-of-iris-publishers-4ace353e4eee
Iris
publishers google scholar citations: https://scholar.google.co.in/scholar?hl=en&as_sdt=0%2C5&q=irispublishers&btnG=
Comments
Post a Comment